Catalyst

Slingshot members are tracking this event:

FDA Priority Review date for Venetoclax Set mid-2016

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
Importance
High Medium Low
Impact on Stocks
ABBV

100%

Additional Information

Additional Relevant Details After being granted priority review and accepting AbbVie's NDA submission for venetoclax, the FDA will make a decisions on venetoclax in mid 2016.
http://www.gene.com/...
Slingshot Insights Explained
Catalyst Date
Occurred on:
Apr 11, 2016
Occurred Source:
Related Projects Image
  • Don’t see a project related to the catalyst you care about?

Related Keywords Venetoclax, Chronic Lymphocytic Leukemia, Bcl-2 Inhibitor, 17p Deletion, B-cell Lymphoma-2